Simple, convenient dosing with once-daily oral Fruzaqla 1
Dose reductions can help manage adverse events (AE)1
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
References:
1. Fruzaqla EU Summary of Product Characteristics (SmPC) last approved version.
Abbreviations:
AE: Adverse Events
C-APROM/BE/FRZ/0010 - October 2025
FRESCO-2 was a global, randomized, double-blind, multicenter phase 3 study, evaluating the efficacy and safety of Fruzaqla + best supportive care (BSC) vs. Placebo + BSC.1,2
In FRESCO-2, the majority of adverse events (AEs) with Fruzaqla were manageable and predictable1-3
